Ala Eddin Sagar/LinkedIn
Mar 22, 2026, 16:21
Ala Eddin Sagar: Apixaban vs Rivaroxaban on This Week in Pulmonary and Critical Care Medicine
Ala Eddin Sagar, Interventional Pulmonologist at King Faisal Specialist Hospital and Research Center – Madinah, shared a post on LinkedIn:
Apixaban or rivaroxaban for acute VTE?
This study is one of three papers discussed in this week’s episode of This Week in Pulmonary and Critical Care Medicine.
We review:
- A randomized trial comparing apixaban vs rivaroxaban for VTE
- An ICU study on oscillatory airway therapy in ventilated patients
- A teaching discussion on how mitral valve disease affects the lungs
Curious how others are interpreting the DOAC trial.
Do you favor apixaban or rivaroxaban for acute VTE?
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria